Real-World check: does new combo improve daily life for myeloma patients?
NCT ID NCT05954780
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times
Summary
This study follows 75 adults with multiple myeloma that has come back or not responded to treatment. They are taking a combination of selinexor, bortezomib, and dexamethasone as part of their regular care. The goal is to see how this treatment affects their quality of life and how well it is tolerated in everyday practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gemeinschaftspraxis für Hämatologie und Onkologie GbR
Ravensburg, Baden-Wurttemberg, 88212, Germany
-
Medizinische Universität Wien, Universitätsklinik für Innere Medizin I
Vienna, 1090, Austria
Conditions
Explore the condition pages connected to this study.